Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
GlycoMimetics, Inc. is a biotechnology company specializing in glycomimetic small molecules that target carbohydrate-related biological processes. Its focus includes developing therapies for cancers and inflammatory diseases, with a pipeline centered on selectin antagonists like uproleselan. The company collaborates globally, holds key patents, and relies on third-party manufacturing, aiming to address high unmet medical needs through innovative, proprietary drug candidates.
This description was generated via AI from an annual report. Updated about 1 year ago.